Whether your product has solubility issues—as do 70% of drugs in development—or your brand is looking to expand shelf space, softgels may be the best finished dosage solution. With fierce competition among CDMOs in the United States, Europe, and Asia, choosing the right partner to develop your prescription therapeutics (Rx) or consumer healthcare product can be a difficult decision.
We bring decades of experience from development through commercialization and have dedicated encapsulation facilities in High Point, NC, and Tilburg, the Netherlands, have the capacity to produce 10 billion to 12 billion softgels annually. Our scientists are skilled in developing softgel formulations in early development to overcome bioavailability challenges and speeding new molecules to clinic. We also develop softgel formulations for late-stage lifecycle management, helping our clients retain market share and maximize product lifetime value.
No. 1
The No. 1 preferred provider of CDMO services for small molecule drug product manufacturing,1 offering a consultative experience to bring your small molecule to market in the form of a softgel
78 new OTC softgel projects
Over the last five years, Patheon pharma service has started 78 new over-the-counter (OTC) softgel projects.
20 tech transfers
In 2022, Patheon pharma services successfully completed 20 small molecule tech transfers (all therapeutic areas)
Our new proprietary soft lozenge technology is uniquely designed to improve patient compliance by providing a soft and soothing sensory mouthfeel, enabling a more comfortable and patient-friendly delivery of active pharmaceutical ingredients (APIs). Soft lozenges are compatible with many different APIs and are suitable for pharmaceutical and nutraceutical products alike.
ChewelsTM chewable gels are approved for pharmaceutical use and are ideal for pediatric and geriatric populations. They are also well suited for people who find swallowing difficult and are looking for a convenient dosage form for administration.
EnteriCareTM technology incorporates the enteric properties directly into the gelatin shell, replacing extra steps such as coating during the manufacturing process. This creates more consistent enteric behavior. EnteriCare products can be developed as transparent softgels, which creates a more appealing aesthetic quality compared to traditionally coated capsules.
With a soft-chewable shell, LiquisoftTM softgels are particularly suitable for liquid fills that require a fast onset of action and/or buccal absorption. Liquisoft softgels come in a variety of flavors that mask bad tastes and odors, adding to patient appeal.
*Patents obtained in the United States, Europe, and other countries
SofgelsTM technology is suitable for liquid formulations, applications requiring faster onset of action, low-dose products, and those with poor bioavailability that would benefit from a lipid system. These capsules are easy to swallow, and twist-off options are available.
SofletTM Gelcaps employ a gelatin-enrobing technology that makes tablets easier to swallow. A broad palette of colors and imprinting choices are available, including inline printing.
*Based upon study by Banner Life Sciences LLC: Consumer Acceptance of SofletTM Tragon 2002
VersatrolTM controlled release softgels possess an innovative tamper-resistant technology, making them an excellent choice for abuse-deterrent formulation and/or preventing dose dumping. They are immune to injection, sniffing, crushing, or dissolving. The controlled release properties are never compromised.
Twist-offs can help reduce dosing errors observed with other oral liquid formulation by providing the exact amount of liquid needed in the capsule. Twist-offs are suitable for newborns and young infants and are also well-suited for dermatologic products.